Drug Database
BO

botulinum toxin type A (Coretox)

✓ Approved

Medytox · 治疗药物

什么是 botulinum toxin type A?

botulinum toxin type A 是一种治疗药物,由Medytox研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Coretox
公司Medytox
给药途径Injectable (Others)
状态Approved

治疗适应症

botulinum toxin type A 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersSkin wrinkling✓ Approved
Musculoskeletal and connective tissue disordersMuscle spasmsPhase III

相关研究文献

PubMedNeurological research and practice2026-11-19

High early burden of post-stroke spasticity and persistent treatment gaps in structured follow-up care.

Stuckart Isabella I, Schoene Daniela D, Altarsha Eyad E, Pfaff Nastasja N et al.

Post-stroke spasticity (PSS) is a frequent and disabling complication after stroke. Real-world data on the implementation of guideline-recommended antispastic treatment within structured follow-up programs are limited. In this prospective cohort study, patients with persistent motor deficits after stroke were followed within a structured post-stroke care program. Spasticity was assessed using the Modified Ashworth Scale (MAS) at predefined follow-up intervals (3 and 12 months after stroke onset). Clinically relevant spasticity was defined as MAS ≥ 2 in at least one joint. Antispastic treatments, including botulinum toxin type A (BoNT-A), were recorded. The implementation gap for BoNT-A was defined as the proportion of patients with a treatment recommendation who had not initiated therapy. Using a cumulative 12-month MAS-based definition among patients with persistent paresis and available follow-up assessments, clinically relevant spasticity was observed in 40/55 patients (72.7%, 95% CI 59-83.9), while 51/55 patients (92.7%, 95% CI 82.4-97.9) showed any increase in muscle tone (MAS > 0). Clinically relevant spasticity was present in 34/53 patients at 3 months (64.2%, 95% CI 49.8-76.9) and in 26/46 patients at 12 months (56.5%, 95% CI 41.1-71.1). Among patients with clinically relevant spasticity, BoNT-A treatment was recommended in 11.8% at 3 months and 26.9% at 12 months, while no patient with a documented recommendation had initiated therapy. PSS occurs early and affects a substantial proportion of patients with persistent motor deficits after stroke. Despite structured follow-up and systematic screening, implementation of guideline-recommended BoNT-A therapy remained absent in patients with documented treatment recommendations, indicating substantial barriers to evidence-based outpatient spasticity care.

PMID 43053249
阅读全文 →
PubMedMycotoxin research2026-11-19

Biological mycotoxin d​etoxification in dried fruits: food safety challenges and barriers to industrial translation.

Qala Kaoutar K, Abdelmoumen Hanaa H

Despite decades of research demonstrating the detoxification potential of microorganisms and enzymes, biological mycotoxin detoxification has achieved only limited industrial implementation, particularly in dried fruits. This persistent gap between laboratory efficacy and practical application remains one of the major unresolved challenges in the field. Rather than providing another descriptive overview of detoxification mechanisms or biological agents, this critical narrative review examines the scientific, technological, regulatory, and commercial barriers limiting industrial translation. A structured literature search was conducted in Scopus, Web of Science, PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by screening the reference lists of relevant publications. Studies were selected according to their relevance to biological mycotoxin reduction, the mechanisms demonstrated, the food matrices investigated, and their implications for safety and industrial applicability, with priority given to publications from 2020 onward. The review highlights a substantial gap between reported laboratory efficacy and demonstrated applicability to dried fruits, as much of the available evidence derives from culture media, simplified food models, or other matrices, including cereals and feed. The low water activity and high sugar content of dried fruits further complicate the transfer of findings from other food systems. Additional barriers include reversible toxin adsorption, insufficient toxicological characterization of transformation products, methodological heterogeneity, limited process robustness, scale-up challenges, regulatory uncertainty, and economic feasibility. Advancing industrial implementation requires matrix-specific validation in naturally contaminated dried fruits under realistic processing and storage conditions, standardized assessment of detoxification mechanisms, and evidence that toxin reduction translates into a demonstrable decrease in toxicological risk. This review identifies research priorities to support the development of safe, scalable, and economically viable biological interventions for dried-fruit processing.

PMID 43052622
阅读全文 →
PubMedNPJ vaccines2026-11-19

Biosynthesis of a nanoscale Vibrio cholerae conjugate vaccine elicits potent immunity through size and receptor effects.

Wang Kangfeng K, Huang Jing J, Li Juntao J, Li Zhenshi Z et al.

Cholera, caused by Vibrio cholerae, remains a significant global health threat, with the O1 serotype being the predominant cause of recent global outbreaks. Although conjugate vaccines against V. cholerae have been developed via chemical methods, the feasibility of applying novel biosynthetic approaches remains uncertain due to the special structure of its O-polysaccharide, which should be recognized by oligosaccharyltransferases. Here, we successfully established an oligosaccharyltransferase PglL-based glycosylation system in an engineered V. cholerae strain to biosynthesize a nanoscale conjugate vaccine, NP-OPSVc(I). The carrier NP was designed by fusing the cholera toxin B subunit (CTB) with a trimer-forming protein (Tri), which could self‑assemble into a nanoparticle during expression. The resulting glycoprotein exhibited high purity, stability, and retained GM1-binding capacity. We found that the size of NP-OPSVc(I) and its GM1 receptor targeting both contribute to a potent humoral immune response, while its efficient delivery is additionally associated with the induction of intestinal mucosal immunity. In mouse models, the NP-OPSVc(I) demonstrated a favorable safety profile and elicited substantially stronger systemic and mucosal immune responses than conventional conjugates, providing great protection against lethal V. cholerae challenge even at a 10‑fold lower dose without requiring an adjuvant. Furthermore, the immune responses were confirmed in non-human primates, supporting its potential for clinical translation. This work not only developed a novel highly effective candidate vaccine against V. cholerae but also significantly expanded the application scope of the PglL-based platform technology, establishing it as a versatile and broadly applicable enzymatic toolkit for vaccine development.

PMID 43052362
阅读全文 →
PubMedJournal of cardiothoracic surgery2026-11-19

Aortic arch types and arch anomalies in patients undergoing carotid endarterectomy: a retrospective single-center analysis and comparison with population prevalences.

Beyaz Metin Onur MO, Kaya Sefer S

Aortic arch anatomy affects the feasibility and safety of endovascular carotid interventions. Data on the distribution of aortic arch types and branching anomalies in patients undergoing carotid endarterectomy (CEA), particularly from the Eastern Mediterranean region, remain limited. This study aimed to determine the prevalence of aortic arch types (I-III) and arch anomalies in a CEA cohort and compare these findings with population prevalences. A retrospective, single-center, observational study was conducted on 532 consecutive patients who underwent unilateral CEA due to carotid stenosis at Hatay Mustafa Kemal University Hospital between January 2020 and December 2025. Preoperative computed tomography angiography images were reviewed to classify arch type and identify branching anomalies. Descriptive statistics were calculated with Wilson 95% confidence intervals. Observed prevalence rates were compared with published reference values using one-sample proportion tests and chi-square goodness-of-fit analysis. Associations between arch type and clinical variables were evaluated using chi-square and Kruskal-Wallis tests. Logistic regression identified independent predictors of arch anomalies. The cohort (mean age 70.6 ± 8.6 years; 66.9% male; 57.9% symptomatic) showed the following arch type distribution: Type I 49.4%, Type II 34.6%, and Type III 16.0%. Half of the patients (50.6%) had complex arch anatomy (Type II-III). The overall distribution differed from that reported by Zhang et al. (χ² = 44.3, p < 0.001), with fewer Type III aortic arches. Aortic arch anomalies were identified in 19.7%: bovine arch in 16.2%, left vertebral artery arising from the arch in 2.8%, aberrant right subclavian artery in 1.1%, and right aortic arch in 0.2%. No demographic or clinical variable independently predicted anomaly presence (all p > 0.2). These disparities likely reflect ethnic anatomical variation between Eastern Mediterranean and East Asian populations. In this Eastern Mediterranean CEA cohort, Type III arch was less frequent than in previously reported series, and arch anomalies were present in approximately one-fifth of patients. The arch type distribution was independent of clinical risk factors, supporting the view that arch anatomy reflects intrinsic variation rather than atherosclerotic burden. These findings may help inform pre-procedural planning when endovascular alternatives to CEA are considered.

PMID 43053176
阅读全文 →
PubMedDiabetologia2026-11-19

The role of sex in explaining the heterogeneity of type 1 diabetes.

Ferrat Lauric A LA, Templeman Erin L EL, Sims Emily K EK

Type 1 diabetes is increasingly recognised as a heterogeneous disease with substantial variability in risk, progression, metabolic control and complications. Biological sex is a critical but understudied contributor to this heterogeneity. This review synthesises epidemiological, mechanistic and clinical evidence that sex influences multiple dimensions of type 1 diabetes, including disease epidemiology, the underlying pathophysiology, clinical presentation, complications and treatment responses. These effects are highly dynamic and shaped by interactions among age, hormonal transitions, genetic susceptibility and environmental exposures. Recognition of sex-specific heterogeneity has important implications for screening, risk prediction, monitoring and therapeutic development. We propose that future type 1 diabetes research moves beyond treating sex solely as a covariate and instead incorporates appropriately powered sex-stratified analyses and hormonal context to determine when sex meaningfully modifies disease risk, progression or treatment response.

PMID 43052479
阅读全文 →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-11-19

Response: Association between type and duration of menopausal hormone therapy and endometrial cancer risk: A population-based study.

Yoon Sang-Hee SH, Yuk Jin-Sung JS

PMID 43053549
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多botulinum toxin type A